Analysis Bliss GVS Pharma Limited (BLISSGVS)
5/30/2024
Analysis of Bliss GVS Pharma Limited (BLISSGVS)
Bliss GVS Pharma Limited has been showing a downward trend in the recent days based on the provided data. The closing prices have been decreasing from 109.15 to 103.50 over the past few days. The Relative Strength Index (RSI) values have been below 50, indicating a bearish momentum in the stock.The Moving Average Convergence Divergence (MACD) indicator has been negative, with the MACD line consistently below the signal line. This suggests a potential continuation of the downward trend in the stock price.
Overall, based on the RSI and MACD indicators, it seems that Bliss GVS Pharma Limited may continue to face downward pressure in the near future. Traders and investors should closely monitor the stock for any potential reversal or further decline.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the growth rates are expected to vary across different time periods, with a generally decreasing trend from the past 5 years to the current and future periods. The company is expected to experience a significant slowdown compared to the past 5 years, but still maintain positive growth rates in the upcoming periods.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the majority clustering around the median and average values. The current price is below both the median and average forecast, indicating that there may be potential upside according to analysts.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for the quarter ending on January 31, 2025, were released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a positive current ratio, but a relatively high total debt to equity ratio. The profit margin and operating margin are both healthy, indicating efficient operations. The company's fiscal year ends in September 2023, with notable figures such as revenue, EBITDA, and net income.
Moving on to stock statistics, key metrics such as short ratio, float shares, and shares outstanding are provided. The percentage held by insiders and institutions, as well as short interest, give insights into market sentiment towards the stock.
Valuation metrics show the company's price-to-earnings ratios, price-to-book ratio, and other valuation multiples. The market capitalization and enterprise value provide an overview of the company's overall value in the market.
The stock price summary includes information on beta, moving averages, and the stock's performance over the past year. The 52-week low and high, as well as the percentage change, give an idea of the stock's volatility.
Lastly, dividends and splits data show the company's dividend history, payout ratio, and dividend yield. Information on dividend dates and splits can be useful for investors interested in income-generating stocks.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four fiscal years.
2. The EBITDA has also shown a consistent growth trend.
3. Net income has been increasing year over year.
4. The company has been able to maintain a healthy gross profit margin.
5. Despite fluctuations in operating expenses, the company has managed to increase its operating income.
6. The basic and diluted earnings per share (EPS) have shown an upward trend.
7. The company has been able to effectively manage its income tax expenses.
8. Non-operating interest income has been relatively stable over the years.
9. The company's continuous operations have been profitable each year.
10. Overall, the financial performance of the company in terms of revenues has been positive and improving.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets, resulting in a growth in shareholders' equity.
5. Shareholders' equity includes common stock and retained earnings, contributing to the overall financial health of the company.
6. The company has been managing its short-term and long-term debts while investing in non-current assets for future growth.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance/payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of stability in operations and variability in financing and investing decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, which is higher than the EPS of $1.26 from the same quarter a year ago. The range of estimates is between $1.27 and $1.36, as provided by 26 analysts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, compared to $1.46 from the previous year. The estimates range from $1.44 to $1.63, based on 25 analysts' forecasts.
3. Looking at the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, an increase from the previous year's EPS of $6.13. The analysts' estimates range from $6.43 to $6.92, with insights from 39 analysts.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is projected to be $7.23, with a range of estimates between $6.40 and $7.90. This forecast is based on the analysis of 39 analysts.
Overall, the trend indicates a growth in earnings per share both quarterly and annually, reflecting a positive outlook for the company's financial performance in the upcoming periods.
MACD of BLISSGVS
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
